PSA is considered a target for prostate cancer treatment because it is exclusively derived from prostate tissue and participates in prostate cancer signaling pathways such as angiogenesis, invasion, and tumor microenvironment regulation (Moradi et al., 2019). This evidence concerns the gene KLK3 and neoplasm.